If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the ...

Big Issues Changemakers in health and disability are working to improve the lives of those marginalised by society.

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's fourth consecutive day of gains.